Skip to main content

Table 6 Plasma miRNA results in MD patients with normal vs. pathological CMR results

From: Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

miRNA plasma levelsa (/103) Normal CMR Abnormal CMR p value
N = 14 N = 49
-206 14.36 (3.07–49.46) 21.76 (4.82–72.71) 0.68
-144-5p 8.94 (0.00–163.41) 9.85 (0.00–171.21) 0.97
-146b 84.15 (40.30–169.65) 38.75 (0.00–177.31) 0.25
-15b 7.44 (0.00–21.87) 0.00 (0.00–18.78) 0.43
-195 9.76 (1.53–19.84) 8.31 (0.57–21.25) 0.86
-20b 49.38 (29.88–79.03) 65.38 (19.43–86.37) 0.66
-21 71.91 (2.89–107.05) 11.48 (0.00–113.69) 0.61
-221 0.00 (0.00–35.26) 0.00 (0.00–11.27) 0.87
-222 1367.66 (689.45–1764.90) 2230.30 (964.52–5884.91) 0.09
-26a 173.94 (47.45–324.42) 326.81 (126.07–602.29) 0.63
-29a 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.94
-29c 0.00 (0.00–2.24) 0.00 (0.00–0.56) 0.93
-342 1987.68 (808.31–2723.93) 2639.34 (1333.85–5106.77) 0.16
-378a-3p 14.15 (0.00–273.74) 39.74 (5.89–290.67) 0.39
-378a-5p 17.32 (2.66–40.41) 39.29 (13.24–101.0) 0.06
-451 104.66 (57.69–312.21) 206.41 (110.79–338.52) 0.27
-93 24.46 (0.38–55.52) 26.95 (0.00–69.92) 0.93
  1. (a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 103 in order to increase readability
  2. Bold text indicates a significant p-value of <0.05